Stories 1 to 8 of 437
7/29/2010 Researchers Say Mouth-to-Mouth May Not Be Necessary Mouth-to-mouth rescue breathing may do more harm than good when performed on someone whose just suddenly collapsed. That's the bottom line from a pair of studies published Wednesday in the "New England Journal of Medicine." It use to be that people were taught to give two breaths for every 30 compressions was adequate. They're saying no breaths, just stick to the chest compressions with the theory being that it's better to continue pumping a victim's heart, rather than stopping intermittently to give mouth-to-mouth, which could actually lower their chances of survival. The findings, however, do not apply to children under the age of eight. Read Full Story
7/29/2010 Experimental Test Detects Ovarian Cancer With New 100% Accuracy Researchers have announce an experimental test for ovarian cancer that's shown great success. The test, that uses antibodies to detect tumor cells in the blood, correctly identified 16 of 17 women who had the cancer. The test was developed by a Belgian company, MabCure which says it also produced no false positives, meaning health women were never diagnosed as having cancer. The test is important because ovarian cancer symptoms are vague and often missed. If detected early, ovarian cancer can be cured but in more that 70% of women, diagnosis only comes after the disease has become advanced. Ovarian cancer kills 15,000 women in the US each year. Read Full Story
7/27/2010 FDA Staff Mixed On AstraZeneca Blood Thinner Staff members of the Food and Drug Administration are giving mixed views on an experimental blood thinner called Brilinta. The main issue for the drug is a lack of benefit for patients in North America. A company study shows a significant reduction in deaths and heart attacks for patients in other countries. Some staff members, in memos prepared for an advisory panel that meets on Wednesday, appear willing to accept the differences. However, FDA reviewer Thomas Marciniak cautioned that while AstraZeneca's main study of Brilinta was generally well run, incomplete follow-up rates are a source of concern. Reviewers in the agency's office of pharmacology recommended Brilinta's approval with post-market study, "aimed to reconcile the findings" from the US. Read Full Story
7/26/2010 Cleaning Products Linked To Risk For Breast Cancer Women who are sticklers for keeping their homes tidy with an abundance of cleaners may be more at risk for developing breast cancer. Researchers writing in the journal "Environmental Health" specifically cited the use of more air fresheners and products for controlling mold and mildew. The study determined combined cleaning products use led to a doubled risk of the disease. An official from the Silent Spring Institute USA says the data was based on interviews with nearly 800 women diagnosed with breast cancer and over 700 comparison females. The study is believed to be "the first public report on cleaning product use and risk of breast cancer." Read Full Story
7/23/2010 Home DNA Tests Might Be Inaccurate The accuracy of home DNA tests that involve people sending saliva samples off to discover their risk for assorted illnesses could be wildly inaccurate. That's the claim of government investigators who sent saliva samples from five people to four unnamed genetic testing companies. The tests produced inconsistent results for the same disease 68% of the time. Read Full Story
7/22/2010 New Patients In Trial Of Avandia Halted The FDA has stopped GlaxoSmithKline from adding new patients to clinical trials of the diabetes drug Avandia. The agency is probing whether the medication has heart risks that would warrant removing it from pharmacy shelves in the U.S. Patients who are currently involved in the clinical trial call Tide can remain in the program. An FDA advisory panel voted last week to allow sales of the drug to continue. Read Full Story
7/21/2010 Bits Of Plastic Lead To Perdue Nugget Recall Perdue Farms is recalling 91,872 pounds of frozen chicken nuggets because some of the products may contain pieces of plastic, the company said Tuesday. Perdue said some of the "Great Value" brand nuggets sold at Wal-Mart stores in the United States could have been contaminated because a small blue plastic ring got into the raw material before the nuggets were formed. The company said the recall represents an "abundance of caution." The recalled products - 50,688 packages in total - have a "best if used by date" of June 9, 2011. On the back of the package appears the numbers 89008A, 0160, and P-33944. No other Great Value brand chicken, or any other Perdue products, are involved in the recall. Customers can return the recalled products to Perdue for a full refund. Read Full Story
7/21/2010 FDA Panel Urges Removal Of Avastin As Breast Cancer Treatment A Food and Drug Administration panel is urging revocation of approval for the cancer drug Avastin as a breast cancer treatment. The advisory panel isn't convinced Avastin provides worthwhile benefits for advanced breast cancer patients. The drug did not extend lives but did delay cancer growht by up to three months. If the FDA follows the recommendation, as it generally does, the drug could still be prescribed for use against colon, lung, brain, and kidney cancers. The recommendation would be a blow to drugmaker Roche's bottom line. Breast cancer treatment using Avastin accounts for about one billion of the drugs more than $6 billion in annual sales. The product is Roche's top selling drug, accounting for 13% of the company's sales in 2009. Read Full Story

MORE Health

1 1 2 3 4 5  x  Page:  … 55 Next »